AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3–Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)

Harry Erba, Pau Montesinos, Radovan Vrhovac, Elzbieta Patkowska, Hee Je Kim, Pavel Zak, Po Nan Wang, Tsvetomir Mitov, James Hanyok, Li Liu, Aziz Benzohra, Arnaud Lesegretain, Jorge Cortes, Alexander Perl, Mikkael Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Mark Levis, Richard Schlenk

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3–Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)'. Together they form a unique fingerprint.

Medicine & Life Sciences